These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 26643449)

  • 41. Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.
    Kater AP; van Oers MHJ; van Norden Y; van der Straten L; Driessen J; Posthuma WFM; Schipperus M; Chamuleau MED; Nijland M; Doorduijn JK; Van Gelder M; Hoogendoorn M; De Croon F; Wittebol S; Kerst JM; Marijt EWA; Raymakers RAP; Schaafsma MR; Dobber JA; Kersting S; Levin MD;
    Haematologica; 2019 Jan; 104(1):147-154. PubMed ID: 30115656
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).
    Maddocks K; Wei L; Rozewski D; Jiang Y; Zhao Y; Adusumilli M; Pierceall WE; Doykin C; Cardone MH; Jones JA; Flynn J; Andritsos LA; Grever MR; Byrd JC; Johnson AJ; Phelps MA; Blum KA
    Am J Hematol; 2015 Apr; 90(4):327-33. PubMed ID: 25639448
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.
    Wendtner CM; Hallek M; Fraser GA; Michallet AS; Hillmen P; Dürig J; Kalaycio M; Gribben JG; Stilgenbauer S; Buhler A; Kipps TJ; Purse B; Zhang J; De Bedout S; Mei J; Chanan-Khan A
    Leuk Lymphoma; 2016; 57(6):1291-9. PubMed ID: 26763349
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab.
    Špaček M; Obrtlíková P; Hrobková S; Cmunt E; Karban J; Molinský J; Šimkovič M; Mociková H; Mohammadová L; Panovská A; Novák J; Trněný M; Smolej L; Doubek M
    Leuk Res; 2019 Apr; 79():17-21. PubMed ID: 30797139
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.
    Martín A; Redondo AM; Dlouhy I; Salar A; González-Barca E; Canales M; Montes-Moreno S; Ocio EM; López-Guillermo A; Caballero D;
    Br J Haematol; 2016 Apr; 173(2):245-52. PubMed ID: 26847165
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions.
    Weide R; Feiten S; Friesenhahn V; Heymanns J; Kleboth K; Thomalla J; van Roye C; Köppler H
    Leuk Lymphoma; 2013 Aug; 54(8):1640-6. PubMed ID: 23151046
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
    Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
    Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients.
    Mattsson A; Sylvan SE; Asklid A; Wiggh J; Winqvist M; Lundin J; Mansouri L; Rosenquist R; Johansson H; Österborg A; Hansson L
    Br J Haematol; 2020 Nov; 191(3):426-432. PubMed ID: 32779190
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study.
    Iannitto E; Morabito F; Mancuso S; Gentile M; Montanini A; Augello A; Bongarzoni V; D'Arco A; Di Renzo N; Fazzi R; Franco G; Marasca R; Mulè A; Musso M; Musto P; Pennese E; Piccin A; Rota-Scalabrini D; Visani G; Rigacci L
    Br J Haematol; 2011 May; 153(3):351-7. PubMed ID: 21371003
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia.
    Smolej L; Doubek M; Panovská A; Simkovič M; Brychtová Y; Belada D; Motyčková M; Mayer J
    Leuk Res; 2012 Oct; 36(10):1278-82. PubMed ID: 22840362
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group.
    Bergmann MA; Goebeler ME; Herold M; Emmerich B; Wilhelm M; Ruelfs C; Boening L; Hallek MJ;
    Haematologica; 2005 Oct; 90(10):1357-64. PubMed ID: 16219572
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
    Dennie TW; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rituximab dose-escalation trial in chronic lymphocytic leukemia.
    O'Brien SM; Kantarjian H; Thomas DA; Giles FJ; Freireich EJ; Cortes J; Lerner S; Keating MJ
    J Clin Oncol; 2001 Apr; 19(8):2165-70. PubMed ID: 11304768
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
    Herishanu Y; Goldschmidt N; Bairey O; Ruchlemer R; Fineman R; Rahimi-Levene N; Shvidel L; Tadmor T; Ariel A; Braester A; Shapiro M; Joffe E; Polliack A;
    Haematologica; 2015 May; 100(5):662-9. PubMed ID: 25661442
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
    Willis CR; Goodrich A; Park K; Waselenko JK; Lucas M; Reese A; Diehl LF; Grever MR; Byrd JC; Flinn IW
    Ann Hematol; 2006 May; 85(5):301-7. PubMed ID: 16518606
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.
    Robak T; Hellmann A; Kloczko J; Loscertales J; Lech-Maranda E; Pagel JM; Mato A; Byrd JC; Awan FT; Hebart H; Garcia-Marco JA; Hill BT; Hallek M; Eisenfeld AJ; Stromatt SC; Jaeger U
    Br J Haematol; 2017 Feb; 176(4):618-628. PubMed ID: 27977057
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis.
    Liang L; Zhao M; Zhu YC; Hu X; Yang LP; Liu H
    Ann Hematol; 2016 Sep; 95(9):1473-82. PubMed ID: 27329288
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial.
    Montillo M; Illés Á; Robak T; Pristupa AS; Wach M; Egyed M; Delgado J; Jurczak W; Morschhauser F; Schuh A; Eradat H; Shreay S; Barrientos JC; Zelenetz AD
    Health Qual Life Outcomes; 2019 Nov; 17(1):173. PubMed ID: 31729982
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study.
    Michallet AS; Aktan M; Hiddemann W; Ilhan O; Johansson P; Laribi K; Meddeb B; Moreno C; Raposo J; Schuh A; Ünal A; Widenius T; Bernhardt A; Kellershohn K; Messeri D; Osborne S; Leblond V
    Haematologica; 2018 Apr; 103(4):698-706. PubMed ID: 29419437
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity.
    Thompson PA; Stingo F; Keating MJ; Ferrajoli A; Burger JA; Wierda WG; Kadia TM; O'Brien SM
    Cancer; 2016 Aug; 122(16):2505-11. PubMed ID: 27182988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.